Incomplete informed consent for psychotropic medications
Summary
The facility failed to obtain informed consent for psychotropic medications for multiple residents whose records were reviewed. The deficiency involved residents receiving medications in several psychotropic categories, including antipsychotics, antidepressants, antianxiety agents, anticonvulsants used as mood stabilizers, and hypnotics, but the records did not consistently show that consent had been obtained for all of the psychotropic medications ordered for each resident. Resident 8 had diagnoses including anxiety disorder, major depressive disorder, and bipolar disorder, and was receiving alprazolam, bupropion, Rexulti, doxepin, and lamotrigine. The record showed a consent dated 8/11/25 for bupropion and alprazolam, but it did not document informed consent for Rexulti, doxepin, or lamotrigine until a later consent dated 9/9/25. The record also lacked documentation that informed consent for psychotropic medications had been obtained from the resident or representative before 8/11/25. Resident 11 was cognitively intact and was receiving quetiapine, buspirone, and duloxetine for anxiety and depression. A consent dated 8/11/25 documented buspirone only and did not include quetiapine or duloxetine. The record lacked documentation of informed consent for psychotropic medications before 8/11/25. During interview, the Regional Clinical Consultant stated there had been issues with the psychotropic medication consents, that consents were initially obtained in August but did not include all required medications, and that all required psychotropic medication consents were completed later in September 2025. Resident 5 had diagnoses including depression, dementia, and diabetes and was ordered amitriptyline for depression, but the record lacked documentation of consent for psychotropic medication. Resident 99 had diagnoses including depression and dementia and was ordered quetiapine for dementia, but the record lacked documentation of psychotropic medication consents from 2/12/25 to 8/8/25. Resident 103 had diagnoses including dementia, anxiety disorder, and psychosis and was receiving olanzapine, Zoloft, and Paxil; the consent dated 8/10/25 documented olanzapine only and did not document consent for Paxil or Zoloft. The consultant stated that the August consents only included antipsychotic medications and did not meet the required guidelines for all psychotropic medications.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.